Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages.
Mojtahedi
Zahra
Z
D006801:Humans; D020382:Interleukin-18 / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D009369:Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*; D012720:Severity of Illness Index; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology*
D020382:Interleukin-18